Aptevo Therapeutics Inc. (APVO): Shareholders' Equity
$17.38M
As of 2025-12-31
$6.04M
As of 2026-06-30
-1.1%
3-year compound annual growth
+0.9%
5-year compound annual growth
-15.0%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.38M | +265.5% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $4.75M | -61.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $12.22M | -32.0% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $17.97M | n/m | 2024-03-05, Balance as of period end |
| 2021-12-31 | $1.22M | -92.7% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $16.59M | +40.1% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $11.84M | -61.1% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $30.41M | -62.9% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $82.03M | +62.2% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $50.57M | n/a | 2018-03-13, Balance as of period end |
| 2016-06-30 | $97.20M | n/a | 2017-03-31, Balance as of period end |
| 2016-03-31 | $89.86M | n/a | 2017-03-31, Balance as of period end |
| 2015-12-31 | $88.62M | n/a | 2017-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $17.38M | +265.5% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $20.93M | +43.4% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $20.02M | -70.6% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | -$23.99M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $10.48M | +136.4% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $1.64M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $24.60M | +29.5% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$37.28M | n/m |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $15.76M | +84.5% |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗